Banned pharmaceutical drugs discovered in the US drug

New Post Public Reply Private Reply Replies (0) Message Board
wowhappens28
123
Banned pharmaceutical drugs discovered in the US drug supply, USDA decides to do nothing

https://www.naturalhealth365.com/banned-pharm...-2699.html

A new article in Consumer Reports has blown the lid off an ongoing food safety scandal – and revealed that traces of banned and restricted pharmaceutical drugs have been found in beef, poultry and pork headed for supermarkets and supper tables throughout the United States.

The drug residues include ketamine – a veterinary anesthetic with hallucinogenic effects – phenylbutazone – an anti-inflammatory medication considered too risky to human health to use – and chloramphenicol, a potent antibiotic associated with a life-threatening form of anemia.

Meanwhile, U.S. federal agencies meant to ensure food safety appear to be turning a blind eye.

Consumer Reports scientists analyzed data from tests performed on thousands of meat samples
To obtain their findings, the scientists examined United States Department of Agriculture (USDA) tests that had been performed on nearly 6,000 random samples of beef, poultry and pork.

The team also examined government documents and conducted interviews with government officials, doctors, industry groups and farmers.

The test results and documents were obtained through the Freedom of Information Act as part of a lawsuit brought by food safety organizations against Sanderson Farms, the third largest poultry producer in the nation. The lawsuit alleges that the company’s claims of producing “natural” and “antibiotic-free” poultry are misleading.

All of the scientists were employed by Consumers Union – the publisher of Consumer Reports magazine. And, Consumers Union is an independent, non-profit organization dedicated to unbiased research and consumer protection.

Bombshell findings on potentially dangerous pharmaceutical drugs met with shrugs from the USDA
Shockingly, 2.6 percent of the samples of poultry, beef and pork contained chloramphenicol in amounts that exceeded the cutoff levels established by Consumer Report’s team of scientists.

Chloramphenicol at any level can cause life-threatening aplastic anemia – the inability to produce sufficient new blood cells – in 1 out of 10,000 people.

In addition, 1.6 percent of the samples contained phenylbutazone, a drug no longer used in humans because of its “double whammy” of potential health hazards. Not only is phenylbutazone associated with aplastic anemia as well, but it is a possible carcinogen.

Traces of ketamine, an anesthetic with hallucinogenic properties, were also found. Sometimes abused as a “party drug,” ketamine is currently restricted by the government.

To be clear: all three drugs are prohibited from use in animals meant for human consumption. But, no one is certain how these prohibited drugs are even ending up in the meat supply.

Some industry experts theorize that contamination could occur through runoff from excrement into soil and water – which then enters drinking water and feed given to livestock.

Intentional or accidental misuse – in which producers use the drugs to accelerate growth – could also be a factor, as could mislabeled or counterfeit drugs.

While the concentration of drug residue liable to cause harm in humans is ‘unknown,’ recent studies indicate that long-term exposure to even low levels could raise the risk of cancer, antibiotic resistance, and harm to developing fetuses.

To date, the response of the USDA’s Food Safety and Inspection Service (or FSIS) has been non-existent.

USDA denies the validity of its own data
Emilio Esteban, Ph.D., chief scientist at FSIS, claims the Consumer Reports’ team’s findings are the result of “unconfirmed” screening tests – and says they should be discounted.

By the way, the scientists used the USDA’s own data to reach their conclusions!

In many cases, Dr. Esteban said, the results were below levels considered to be of concern by FSIS – and didn’t meet agency criteria that would necessitate follow-up testing.

The cut-off levels – also known as minimum levels of applicability – set by the FSIS are significantly higher than those utilized by the Consumer Reports team – and much higher than those used by other government agencies. In fact, many natural health advocates and food safety experts – including Consumers Union – have urged FSIS to use more widely accepted scientific standards.

Scholars, scientists and natural health advocates call for action
Consumer Reports’ Director of Food and Safety Research and Testing, James E. Rogers, PhD, expressed his disappointment at the lack of response from FSIS.

“You would hope the results would prompt the agency to look into why these drugs may be present, what risks they could pose, and what could be done to protect consumers,” commented Dr. Rogers.

Charles Benbrook, Ph.D., a scholar with the Bloomberg School of Public Health at Johns Hopkins University, agrees.

Dr. Benbrook noted that the findings should have resulted in “aggressive” action to figure out how the drugs are ending up in meat.

And Andrew Gunther – executive director of A Greener World, a non-profit organization that promotes sustainable farming – called the drugs “potentially very dangerous.” He professed to be “floored” by the alarming results, saying that the contaminants appeared in more samples, and at higher levels, than he would have expected.

FSIS has taken little action, as agency officials downplay results
The responsibility for enforcing food safety regulations and assigning penalties lies with the Food and Drug Administration (FDA).

But Consumer Reports points out that the agency has issued very few citations, to date, for drugs that shouldn’t be in meat in the first place. (Meat producers are more likely to be cited for exceeding residue limits for approved drugs).

And FDA penalties – such as warning letters, injunctions, and the placing of repeat violators on a public list – amount to little more than a “slap on the wrist.”

Lest there be any doubt regarding the ineffectuality of the current penalties, Parthapratim Basu, D.V.M. – former Chief Public Health Veterinarian at FSIS – offers up an infuriating example.

Do you think meat producers really care about FDA warning letters?
According to Dr. Basu, many meat producers seem to view a warning letter from the FDA with a distinct lack of alarm. Some even consider it a point of pride – and utilize the letters to “cover holes in the barn.”

Not only has FSIS failed to ensure that meat intended for human consumption is free of drugs, but the agency continues to downplay and minimize the actual presence of these contaminants.

A FSIS spokesperson quoted by Consumer Reports characterizes the data as “preliminary,” “unconfirmed” and “misleading,” and announced that it did not represent any public health risk to consumers.

And, an official at the National Chicken Council says conclusions based on preliminary results “would amount to fearmongering and needless alarm.”

There you have it: the discovery of the true amounts of potentially dangerous drug residues in the American meat supply is being met with stalling, hesitation and outright denial. In light of this (I’m sure you would agree), the decision to choose meat from organic farms – which are required by federal law to raise their livestock without drugs or other chemicals – should be a no-brainer.

Sources for this article include:
Consumer Reports
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Faces Investor Class Action After Stock Tumbles

Updated Category News Views 15

Shake-Up at Gildan: Investors Take Legal Action Gildan Activewear Inc. (NYSE:GIL) got themselves in hot water, folks. They've landed on the wrong side of an investor class action lawsuit after claims of shady business tactics sent their stock plummeting like a rock in June. We're talking about an 18.75% nosedive here. That's not just a slip—it's a fall worth wearing a...

Continue Reading
Ad Council Expands Board, Taps Meta Exec as Vice Chair

Updated Category News Views 0

An Unexpected Shuffle at the Ad Council Alright, folks, let's talk shop about the recent shake-up in the nonprofit realm. The Ad Council, which has been around longer than some of the giants controlling today's marketing landscapes, just plumped up its Board of Directors with 23 new heavy-hitters. We're talking about leaders from every nook and cranny of the...

Continue Reading
North Fork Mono Casino Opens: A $750 Million Bet

Updated Category News Views 40

A New Spin in Madera Cue the fanfare, folks! The North Fork Mono Casino just threw open its doors earlier than expected today, marking a hefty $750 million wager right in the heart of California's Central Valley. It's a big deal managed by Station Casinos, part of Red Rock Resorts, Inc. (NASDAQ: RRR)—teaming up with the North Fork Rancheria of Mono Indians for a...

Continue Reading
Epson Innovates Order Pickup at Florida Food Hall

Updated Category News Views 126

Changing the Food Hall Game Innovation isn't just a Silicon Valley buzzword; it found its place at the Central Park St. Pete Food Hall in Florida. These guys have figured out the magic formula to streamline multi-vendor dining with Epson's point-of-sale label printers. We're talking about keeping guests from playing musical chairs with food orders, folks. It's a...

Continue Reading
Altea Targets US Market, Appoints Rodrick VP Amid Expansion

Updated Category News Views 58

Wading into the murky waters of U.S. healthcare insurance isn't for the faint of heart, but Altea's making its move. Backed by MISSION, they're banking on a niche strategy by tapping veteran Justin Rodrick as Vice President. Their tactic? Aim squarely at the under-served segment of small to mid-sized medical and healthcare facilities. The play's bold, and if Rodrick's got...

Continue Reading
Medical Device Manufacturing: $135B Market by 2031

Updated Category News Views 89

Skyrocketing Demand in Medical Device Manufacturing You're looking at a market that's gearing up to hit a whopping $135.47 billion by 2031. That's a big leap from its $85.59 billion stature in 2026, showing a strong 9.6% compound annual growth rate (CAGR). Now, if that doesn't get your investor rollercoaster senses tingling, I don't know what will. Key Growth Drivers The...

Continue Reading
Posterity Health Boosts Network to Six New Markets

Updated Category News Views 132

Expansion at Breakneck Speed Just like that, we've got Posterity Health making power moves across the country, staking claim in six major markets. Denver's very own fertility platform is on a roll, and this ain't just any rollout. We're talking partnerships like confetti in the air, dotting spots from the sunny Cali shores of Orange County to the bustling streets of...

Continue Reading
Counterfeits in Aerospace: Industry Tackles Supply Risks

Updated Category News Views 105

The Trouble with Counterfeit Parts in Aerospace Ah, aerospace—the domain where milliseconds matter, and materials must be tougher than a New York steelworker's boots. But guess what's throwing a wrench in the works? Counterfeit parts. That's right, the sector's latest buzzkill is as sneaky as a penny stock scam, and it's about time the industry's heavyweights had a...

Continue Reading
Meta's Bold Move: $25B Offering and New Stocks

Updated Category News Views 62

Meta's New Financial Adventure Well, when Meta talks money, you better believe the market listens. This time, they’ve got a whopping pair of offerings on the table—one for depositary shares and another for their Class A common stock. Meta, under the ticker NASDAQ:META, isn't holding back, with a $25 billion upsized offering that's bound to rattle some cages. A Deeper...

Continue Reading
Cracking the Last-Mile 'Fragmentation Tax' Challenge

Updated Category News Views 12

Tackling Last-Mile Delivery Woes It's like trying to put a square peg in a round hole. That's what last-mile delivery feels like right now with the burden we're seeing in EMEA—costs shooting up by 9% just this past year. Anyone in logistics knows that red ink doesn't just dry up on its own. According to FarEye, 96% of companies are coughing up more dough per delivery,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Exelon's Earnings: Insights and Future Potential

Updated Category News Views 142

Understanding Exelon's Upcoming Earnings Report Exelon Corporation (NASDAQ: EXC) is preparing to reveal its quarterly earnings in the near future. Investors are keenly awaiting the results, as they want insights into the company’s performance and projections for the following period. Analysts predict that Exelon will report an earnings per share (EPS) of $0.39,...

Continue Reading
Vallourec Invites Warrant Holders to General Meeting

Updated Category News Views 157

Vallourec Invites Warrant Holders to General Meeting Vallourec has announced a significant upcoming event for its warrant holders, also known as BSA. This meeting is set to take place soon, providing an opportunity for holders to engage with the company's future decisions. Details of the Meeting The general meeting will occur at the Vallourec headquarters, where the...

Continue Reading
Investigation Initiated for Molina Healthcare Investors Following Financial Reports

Updated Category News Views 246

Pomerantz LLP Begins Investigation on Behalf of Molina Investors Pomerantz LLP has embarked on an investigation focusing on the interests of investors in Molina Healthcare, Inc. (NYSE: MOH). This inquiry aims to ascertain whether Molina and certain executives may have been involved in any unlawful activities related to securities fraud. Key Financial Findings and Investor...

Continue Reading
How SymphonyAI's Insights Drive E-commerce Growth in Grocery

Updated Category News Views 159

Unlocking E-commerce Potential in Grocery Retail In a transformative announcement, SymphonyAI, a leader in predictive and generative AI SaaS products for enterprises, has unveiled groundbreaking insights from its annual grocery e-commerce study. This research indicates a noteworthy 8% growth opportunity for retailers leveraging AI-driven strategies in their connected...

Continue Reading
Exploring the Impact of Honda and Nissan's Potential Merger

Updated Category News Views 408

Honda and Nissan's Strategic Talks Honda (NYSE:HMC) and Nissan (OTC:NSANY) have entered discussions that may lead to a potential merger, a significant move reflecting the shifting landscape of Japan's automotive industry. As these two giants explore deeper ties, it marks a notable strategy to face the competition posed by Tesla and various Chinese car manufacturers....

Continue Reading